The Phase III InMIND study: tafasitamab plus lenalidomide and rituximab in R/R follicular lymphoma
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2025-07-14
Просмотров: 103
Описание:
Marek Trněný, MD, Charles University Hospital, Prague, Czech Republic, discusses the Phase III InMIND study (NCT04680052), evaluating tafasitamab in combination with lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma. Dr Trněný reports a significant improvement in progression-free survival, and then he goes on to discuss several stratification factors. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
